Experts explain how menin inhibitors target KMT2A and NPM1 AML, why retesting matters, and how to choose approved drugs or trials.
Testing, Patient Selection, and Individualizing Care for Menin Inhibition in NPM1-Mutated and KMT2A-Rearranged Acute Myeloid Leukemia
Experts explain who benefits from menin inhibitors in AML, which tests to order at relapse, and how to choose revumenib vs ziftomenib.
Advertisement
Advertisement
Trending on CancerNetwork
1
Multimodal Biopsy Combo Shows Low Morbidity in Suspected Prostate Cancer
2
BCMA/GPRC5D CAR T-Cell Therapy Shows Early Efficacy in R/R Multiple Myeloma
3
Integrating Talazoparib Plus Enzalutamide Into HRR-Mutated mHSPC Care
4
Proton Therapy Does Not Improve Survival in Hepatocellular Carcinoma
5